The objective of Janssen is to transform cancer into a preventable and chronic disease through the development of therapeutic alternatives that extend and improve the quality of life of the patients. We currently have medications that are capable of interrupting the carcinogenic process of some types of cancer.

In our Onco-Hematology portfolio, we count with therapeutic alternatives for the treatment of prostate cancer, multiple myeloma, chronic lymphocytic leukemia, mantle cell lymphoma and other B-Cell malignancies, amongst others.